Nabil A. Elshourbagy

Biochemistry, Genetics and Molecular Biology · Life Sciences

46h-index14.9kcitations89works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Receptor Mechanisms and Signaling(18), Lipoproteins and Cardiovascular Health(16), Neuropeptides and Animal Physiology(15), Nitric Oxide and Endothelin Effects(11), Computational Drug Discovery Methods(8)

Publications89 total

Molecular Biology of Endothelin Receptors
2024
Corrigendum to “Novel oral nano-hepatic targeted anti-PCSK9 in hypercholesterolemia” [Nanomedicine 40 (2022 Feb); 102480. doi: 10.1016/j.nano.2021.102480]
Nanomedicine Nanotechnology Biology and Medicine·2022
Novel oral nano-hepatic targeted anti-PCSK9 in hypercholesterolemia
Nanomedicine Nanotechnology Biology and Medicine·2021· 18 cited
"Discovery and Development of an Oral, Small Molecule PCSK9/LDLR Antagonist"
Advancements in Cardiovascular Research·2021Open Access
Abstract 16810: Identification of a New Class of Small Molecule Antagonists for Protease Proprotein Convertase Subtilisin-Like Kexin Type 9
Circulation·2017
Abstract 14992: Identification and Characterization of Orally Bio-Available Anti-Atherosclerosis Agents
Circulation·2016
Abstract 15053: New Insights into the Development of the Protease Proprotein Convertase Subtilisin-Like Kexin Type 9 Antagonists
Circulation·2016
Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol
Pharmacology & Therapeutics·2016· 29 cited
Abstract 10829: Biological and Pharmacological Properties of the Protease Proprotein Convertase Subtilisin-Like Kexin Type 9 Antagonists <i>(Best of Basic Science Abstract)</i>
Circulation·2015
Abstract 10829: Biological and Pharmacological Properties of the Protease Proprotein Convertase Subtilisin-Like Kexin Type 9 Antagonists (Best of Basic Science Abstract)
2015· 1 cited
Abstract 10306: Identification and Characterization of Orally Bioavailable Small Molecule Protease Proprotein Convertase Subtilisin-like Kexin Type 9 Inhibitors <i>(Best of Basic Science Abstract)</i>
Circulation·2015· 4 cited
Abstract 9761: Novel Modulators of Low Density Lipoprotein Receptor Metabolism
Circulation·2014· 3 cited
Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia
Medical Principles and Practice·2013· 61 citedOpen Access
Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy
SHILAP Revista de lepidopterología·2010Open Access
Enhanced protein expression in mammalian cells using engineered SUMO fusions: Secreted phospholipase A<sub>2</sub>
Protein Science·2008· 51 citedOpen Access
Structure and Evolution of Human Apolipoprotein Genes: Identification of Regulatory Elements of the Human Apolipoprotein E Gene
Novartis Foundation symposium·2007· 4 cited
Dendroaspis natriuretic peptide binds to the natriuretic peptide clearance receptor
Biochemical and Biophysical Research Communications·2007· 38 cited
Cloning and pharmacological characterization of the cat urotensin-II receptor (UT)
Biochemical Pharmacology·2005· 18 cited
Localisation of NMU1R and NMU2R in human and rat central nervous system and effects of neuromedin-U following central administration in rats
Psychopharmacology·2004· 71 cited
Heterologous Expression of G Protein?Coupled Receptors in U-2 OS Osteosarcoma Cells
Receptors and Channels·2004· 28 cited
page 1 of 5Next →

Frequent Co-authors

Derk J. Bergsma(11), Shelagh Wilson(10), John M. Taylor(10), Jeffrey I. Gordon(9), Paul R. Murdock(8), Henry M. Sarau(8), Nambi Aiyar(8), Mark S. Boguski(8), Usman Shabon(6), Philip Szekeres(6), James J. Foley(6), John E. Adamou(6), Dean E. McNulty(5), Jon Chambers(5), Catherine Ellis(5), Dulcie B. Schmidt(5), Philip S. Guzelian(5), Alison I. Muir(4), Parvathi Nuthulaganti(4), Wu‐Schyong Liu(3)